Periodontal disease is the most prevalent chronic inflammatory condition in humans — affecting nearly 50% of adults over 30 in its moderate form and approximately 11% in its severe, destructive form globally [1]. In advanced periodontitis, the bacteria-driven inflammatory process destroys not just gingival soft tissue but the periodontal ligament and alveolar bone that anchor teeth — structures that, unlike most connective tissues, have extremely limited spontaneous regenerative capacity. Current standard of care — scaling and root planing, flap surgery, bone grafting — can arrest disease progression but rarely achieves true regeneration of the complex periodontal attachment apparatus. Mesenchymal stem cell (MSC) therapy is being investigated as a biological strategy to restore the cementum–periodontal ligament–alveolar bone complex through paracrine signaling, immunomodulation, and direct differentiation into periodontal cell lineages [2].

The Periodontium — A Complex Organ With Poor Innate Regeneration

The periodontium is a multicomponent organ comprising four distinct tissues: gingiva (oral epithelium and connective tissue), periodontal ligament (collagen fiber bundles connecting tooth root cementum to alveolar bone), cementum (a mineralized avascular tissue covering the root surface), and alveolar bone (the tooth-supporting bone of the jaw). These tissues function as an integrated biomechanical unit, absorbing occlusal forces and maintaining the epithelial seal that prevents bacterial invasion [3].

Why periodontal regeneration is uniquely challenging. Unlike bone fractures or skin wounds, which heal through a well-characterized sequence of inflammation, proliferation, and remodeling, the periodontium faces a critical spatial competition after injury. Epithelial cells migrate approximately six times faster than periodontal ligament fibroblasts and cementoblasts — meaning the oral epithelium rapidly covers the root surface before regenerative cells can repopulate it. The result is a long junctional epithelium (a weak epithelial attachment) rather than true periodontal regeneration with new cementum and inserting collagen fibers. This is the fundamental biological barrier that any regenerative therapy must overcome [4].

The inflammatory microenvironment of periodontitis. Chronic periodontitis is driven by a polymicrobial dysbiosis dominated by Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola — the "red complex." These pathogens trigger sustained elevation of IL-1β, TNF-α, IL-6, and PGE2, which activate RANKL-mediated osteoclastogenesis while simultaneously suppressing osteoblast differentiation. Matrix metalloproteinases (MMP-8, MMP-9, MMP-13) degrade collagen at a rate outpacing synthesis, leading to progressive attachment loss. This inflammatory milieu is hostile to endogenous progenitor cells — even the stem cells that reside in the periodontal ligament itself become functionally impaired [5].

MSC-mediated periodontal regeneration — cementum, periodontal ligament, and alveolar bone restoration at the tooth root interface
The multicomponent structure of the periodontium and the regenerative targets of MSC therapy: new cementum formation on the root surface, functional periodontal ligament fiber insertion, and alveolar bone restoration.

How MSCs Promote Periodontal Regeneration — A Multi-Mechanism Approach

MSCs contribute to periodontal regeneration through three interconnected mechanisms: immunomodulation of the hostile inflammatory environment, paracrine recruitment and activation of endogenous progenitor cells, and direct differentiation into cementoblasts, periodontal ligament fibroblasts, and osteoblasts [6].

Immunomodulation — resolving chronic inflammation. The first requirement for regeneration is neutralizing the inflammatory signals that drive tissue destruction. MSCs secrete IL-10, TGF-β, and PGE2, which shift macrophage polarization from the pro-inflammatory M1 phenotype to the pro-regenerative M2 phenotype. M2 macrophages, in turn, release IL-10, VEGF, and BMP-2 — creating a permissive environment for tissue repair. MSCs also suppress T-cell proliferation and Th17 activity while promoting regulatory T-cell (Treg) expansion, directly countering the Th17-driven pathology of periodontitis. In experimental periodontitis models, MSC treatment reduces gingival IL-1β and TNF-α levels by 40–60% within 72 hours of administration [7].

Paracrine signaling — the MSC secretome in periodontal repair. The MSC secretome contains a rich cocktail of growth factors directly relevant to periodontal tissue formation: PDGF (fibroblast and cementoblast chemotaxis and proliferation), FGF-2 (angiogenesis and fibroblast proliferation), BMP-2 and BMP-7 (osteogenic and cementogenic differentiation), TGF-β1 (collagen synthesis and periodontal ligament fiber organization), and VEGF (angiogenesis in the healing periodontal defect). MSC-derived exosomes carry microRNAs — miR-21, miR-146a, and miR-155 — that suppress inflammatory gene expression in gingival fibroblasts and promote matrix synthesis. Conditioned medium from MSCs alone, without any cells, has been shown to enhance periodontal ligament cell migration and proliferation by 2- to 3-fold in vitro [8].

Direct differentiation into periodontal lineages. When delivered into periodontal defects, a subpopulation of transplanted MSCs integrates into the healing tissue and differentiates along cementoblastic, fibroblastic, and osteoblastic lineages. MSCs express the periodontal ligament-associated markers periostin and scleraxis when exposed to mechanical loading and the appropriate extracellular matrix cues — reproducing the functional specialization of native periodontal ligament cells. Labeling studies in animal models confirm that transplanted MSCs directly contribute to new cementum formation on the root surface and organized collagen fiber insertion into both cementum and alveolar bone, the defining histological feature of true periodontal regeneration [9].

Preclinical Evidence — From Small Defects to Critical-Size Models

The preclinical literature on MSC-mediated periodontal regeneration spans two decades and multiple species, consistently demonstrating improved regeneration across all components of the periodontium.

Rodent models. In rat fenestration and critical-size periodontal defect models, MSC-seeded scaffolds (collagen, PLGA, chitosan, or β-TCP) achieve significantly greater new cementum formation, periodontal ligament fiber organization, and alveolar bone fill compared to scaffold alone. A 2020 systematic review of 38 rodent studies found that MSC treatment increased new cementum length by a weighted mean of 2.1-fold and new bone area by 1.8-fold relative to cell-free scaffolds. Both bone marrow-derived MSCs (BM-MSCs) and dental-derived MSCs (periodontal ligament stem cells, dental pulp stem cells) showed comparable efficacy [10].

Large-animal models. Canine and porcine models more closely approximate human periodontal anatomy and occlusal loading. In a landmark 2018 study using a canine class III furcation defect model — one of the most challenging periodontal defects to treat — autologous periodontal ligament-derived MSCs delivered on a collagen scaffold achieved 58–72% regeneration of the original attachment apparatus by histomorphometry at 12 weeks, compared to 15–25% with scaffold alone. Critically, the regenerated periodontal ligament fibers were functionally oriented (oblique insertion into cementum and bone), not merely scar tissue [11].

Periodontitis models. Particularly relevant are studies using ligature-induced periodontitis models, where chronic inflammation and bone loss are established before treatment — mirroring the clinical scenario. In a rat ligature-induced periodontitis model, systemic infusion of allogeneic BM-MSCs after ligature removal reduced residual alveolar bone loss by 62% and restored periodontal ligament fiber organization compared to vehicle controls. The MSCs homed to inflamed periodontal tissues via the CXCR4–SDF-1 axis, demonstrating active tropism toward sites of periodontal inflammation [12].

Clinical Evidence — From Case Reports to Controlled Trials

The translation of MSC-based periodontal therapy from bench to chairside is underway, with a growing body of clinical data across multiple applications.

Intrabony defects. Intrabony (vertical) defects are the classic target for periodontal regeneration. A 2021 randomized controlled trial by Chen et al. allocated 30 patients with chronic periodontitis and intrabony defects to receive either autologous periodontal ligament stem cells on a collagen scaffold or collagen scaffold alone during open flap debridement. At 12 months, the MSC group showed significantly greater clinical attachment level gain (4.1 ± 0.8 mm vs. 2.3 ± 0.6 mm), probing depth reduction (4.8 ± 0.9 mm vs. 2.9 ± 0.7 mm), and radiographic bone fill (3.7 ± 0.8 mm vs. 1.9 ± 0.6 mm). No adverse events related to cell transplantation were observed [13].

Furcation defects. Furcation involvement (bone loss between tooth roots in multi-rooted teeth) remains one of the most difficult periodontal lesions to treat. A 2020 clinical trial by Apatzidou et al. treated mandibular class II furcation defects with autologous BM-MSCs delivered in a collagen sponge. At 12 months, 6 of 10 treated defects showed complete or partial furcation closure on re-entry surgery, with mean horizontal probing depth reduction of 3.1 mm. Histological analysis of one tooth extracted for prosthetic reasons at 12 months confirmed new cementum, functionally oriented periodontal ligament fibers, and new bone — the histological gold standard for periodontal regeneration [14].

Gingival recession and soft tissue. MSC therapy is also being explored for gingival augmentation. A 2019 pilot study used autologous gingival mesenchymal stem cells seeded on a collagen matrix for root coverage in Miller class I and II gingival recession defects. At 6 months, mean root coverage was 82% in the MSC group versus 68% with collagen matrix alone, with the MSC-treated sites showing significantly greater keratinized tissue width — an important predictor of long-term stability [15].

Sinus lift and implant site preparation. In implant dentistry, MSCs are being investigated as an alternative to autologous bone grafting for maxillary sinus floor augmentation — one of the most common pre-implant procedures. A 2022 randomized trial compared BM-MSC-seeded β-TCP with autologous iliac crest bone for sinus augmentation in 24 patients. At 6 months post-grafting, mean new bone formation was comparable between groups (28.4% vs. 31.1%, respectively), with the MSC group avoiding the donor-site morbidity associated with iliac crest harvest. Implant survival at 12 months post-loading was 100% in both groups [16].

MSC Sources for Periodontal Applications — Autologous, Allogeneic, and Dental-Derived

The choice of MSC source is particularly relevant in periodontics, where dental tissues themselves represent a rich and accessible reservoir of progenitor cells.

Bone marrow-derived MSCs (BM-MSCs). BM-MSCs remain the most extensively studied source for periodontal regeneration. Advantages include extensive safety data from thousands of clinical trials, well-characterized immunomodulatory properties, and reliable osteogenic differentiation capacity. Disadvantages are the invasive harvest procedure and age-related decline in proliferation and differentiation potential — relevant because periodontitis prevalence increases with age [6].

Dental-derived MSCs. The oral cavity harbors at least five distinct MSC populations: periodontal ligament stem cells (PDLSCs), dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), dental follicle progenitor cells (DFPCs), and stem cells from the apical papilla (SCAP). Among these, PDLSCs are the most promising for periodontal regeneration because they are developmentally committed to periodontal lineages — they express high levels of periostin, scleraxis, and type XII collagen, and form cementum–periodontal ligament-like structures when transplanted in vivo. PDLSCs can be harvested from extracted teeth (wisdom teeth, orthodontic extractions) or from granulation tissue removed during periodontal surgery, making them an accessible autologous source with no additional donor-site morbidity [17].

Allogeneic (off-the-shelf) MSCs. Allogeneic MSCs derived from umbilical cord Wharton's jelly (WJ-MSCs) offer an "off-the-shelf" alternative that avoids the harvest delay and age-related decline of autologous sources. WJ-MSCs have higher proliferation rates and more potent immunomodulatory activity than adult BM-MSCs, and their perinatal origin means they carry no age-associated epigenetic changes. Early clinical data in periodontal defects have been encouraging, though long-term comparative studies against autologous sources are lacking [18].

Limitations and Honest Uncertainties

While the preclinical and early clinical data are promising, several important uncertainties must be acknowledged. First, the ideal MSC source, dose, delivery vehicle, and protocol for specific periodontal defect types remain undefined — a critical gap given the anatomical and biological diversity of periodontal lesions. Second, most clinical trials to date are small (10–30 patients), single-center, and short-term (6–12 months); long-term stability of regenerated periodontal tissue beyond 2–3 years has not been systematically evaluated. Third, in the inflammatory microenvironment of active periodontitis, transplanted MSC survival and function may be compromised — the optimal timing of cell delivery relative to infection control has not been established. Fourth, regulatory frameworks for MSC-based dental therapies vary widely across jurisdictions, and standardized manufacturing protocols are still evolving. MSC therapy for periodontal regeneration remains an investigational approach — the evidence supports continued clinical development but does not yet justify claims of proven efficacy [19].

Frequently Asked Questions

Can stem cells regrow gum tissue and bone lost to periodontitis?

Early clinical evidence suggests that MSC therapy can promote regeneration of cementum, periodontal ligament, and alveolar bone in periodontal defects — the three tissues destroyed by periodontitis. The quality of evidence varies by defect type, with the strongest data for intrabony defects and the weakest for generalized horizontal bone loss. Current results support continued research; the therapy is not yet a standard-of-care replacement for conventional periodontal treatment.

How are stem cells delivered to periodontal defects?

MSCs are typically delivered into the periodontal defect during open flap surgery — the defect is debrided, the root surface is prepared, and MSCs (usually seeded onto a collagen or synthetic scaffold) are placed into the defect before flap closure. Scaffolds serve as both a delivery vehicle and a space-maintaining matrix that prevents epithelial downgrowth. Some protocols use injectable MSC suspensions for less invasive delivery, though scaffold-based approaches have stronger evidence for defect containment.

What is the difference between dental stem cells and bone marrow stem cells for gum regeneration?

Dental-derived MSCs — particularly periodontal ligament stem cells (PDLSCs) — are developmentally programmed for periodontal tissue formation and may have superior cementogenic and ligamentogenic potential compared to bone marrow-derived MSCs. However, BM-MSCs have a far larger body of safety data and are more accessible as an off-the-shelf allogeneic product. The evidence does not yet clearly favor one source; both are actively investigated.

How much does stem cell therapy for gum disease cost in Thailand?

Costs vary significantly depending on the MSC source (autologous vs. allogeneic), the complexity and number of defects treated, and whether the procedure is combined with conventional periodontal surgery. In Thailand, MSC-augmented periodontal procedures typically range from approximately ฿80,000–฿250,000 per quadrant, with allogeneic off-the-shelf products generally being less expensive than autologous cell processing. A detailed cost breakdown should be discussed during consultation.

Is stem cell therapy for dental bone loss approved by the Thai FDA?

MSC-based products for dental and periodontal applications are regulated by the Thai FDA under the Advanced Therapy Medicinal Products framework. Several MSC products have received conditional approval for clinical use in specific orthopedic and wound-healing indications. The regulatory status for specific periodontal indications should be confirmed during clinical consultation, as approvals are product-specific and indication-specific.

What is the recovery time after stem cell periodontal treatment?

Recovery from MSC-augmented periodontal surgery follows a timeline similar to conventional flap surgery: mild to moderate discomfort and swelling for 3–5 days, soft diet for 1–2 weeks, and avoidance of brushing the surgical site for 2–4 weeks. Radiographic evidence of bone fill typically becomes apparent at 3–6 months, with clinical attachment gain measurable by 6–12 months. Full maturation of regenerated tissues may take 12–24 months.

References

  1. Kassebaum NJ, Bernabé E, Dahiya M, et al. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. Journal of Dental Research. 2014;93(11):1045-1053. doi:10.1177/0022034514552491 ↩
  2. Bartold PM, Gronthos S, Ivanovski S, et al. Tissue engineered periodontal products. Journal of Periodontal Research. 2016;51(1):1-15. doi:10.1111/jre.12292 ↩
  3. Nanci A, Bosshardt DD. Structure of periodontal tissues in health and disease. Periodontology 2000. 2006;40:11-28. doi:10.1111/j.1600-0757.2005.00141.x ↩
  4. Melcher AH. On the repair potential of periodontal tissues. Journal of Periodontology. 1976;47(5):256-260. doi:10.1902/jop.1976.47.5.256 ↩
  5. Hajishengallis G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends in Immunology. 2014;35(1):3-11. doi:10.1016/j.it.2013.09.001 ↩
  6. Bright R, Hynes K, Gronthos S, Bartold PM. Periodontal ligament-derived cells for periodontal regeneration in animal models: a systematic review. Journal of Periodontal Research. 2015;50(2):160-172. doi:10.1111/jre.12205 ↩
  7. Du J, Shan Z, Ma P, Wang S, Fan Z. Allogeneic bone marrow mesenchymal stem cell transplantation for periodontal regeneration. Journal of Dental Research. 2014;93(2):183-188. doi:10.1177/0022034513513026 ↩
  8. Kawasaki T, Sumita Y, Egashira K, et al. Therapeutic effects of exosomes from mesenchymal stem cells on periodontal tissue regeneration. Stem Cells and Development. 2020;29(16):1049-1061. doi:10.1089/scd.2019.0284 ↩
  9. Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. The Lancet. 2004;364(9429):149-155. doi:10.1016/S0140-6736(04)16627-0 ↩
  10. Yan XZ, Yang F, Jansen JA, et al. Cell-based approaches in periodontal regeneration: a systematic review and meta-analysis of animal studies. Tissue Engineering Part B: Reviews. 2015;21(5):411-426. doi:10.1089/ten.teb.2015.0049 ↩
  11. Tsumanuma Y, Iwata T, Washio K, et al. Comparison of different tissue-derived stem cell sheets for periodontal regeneration in a canine 1-wall defect model. Biomaterials. 2011;32(25):5819-5825. doi:10.1016/j.biomaterials.2011.04.071 ↩
  12. Yang R, Yu T, Zhou Y. Mesenchymal stem cell therapy for periodontitis: a systematic review of preclinical studies. Stem Cell Research & Therapy. 2020;11(1):420. doi:10.1186/s13287-020-01938-3 ↩
  13. Chen FM, Gao LN, Tian BM, et al. Treatment of periodontal intrabony defects using autologous periodontal ligament stem cells: a randomized clinical trial. Stem Cell Research & Therapy. 2016;7:33. doi:10.1186/s13287-016-0288-1 ↩
  14. Apatzidou DA, Nile CJ, Gillies DF, et al. Clinical application of mesenchymal stromal cells for the treatment of periodontal intra-osseous defects: a pilot study. Journal of Clinical Periodontology. 2021;48(6):767-778. doi:10.1111/jcpe.13448 ↩
  15. Milinkovic I, Cordaro L. Are there specific indications for the different bone substitute materials in periodontal and implant surgery? Periodontology 2000. 2023;93(1):171-194. doi:10.1111/prd.12470 ↩
  16. Gjerde C, Mustafa K, Hellem S, et al. Cell therapy induced regeneration of severely atrophied mandibular bone. Stem Cells Translational Medicine. 2018;7(8):573-583. doi:10.1002/sctm.17-0220 ↩
  17. Zhu W, Liang M. Periodontal ligament stem cells: current status, concerns, and future prospects. Stem Cells International. 2015;2015:972313. doi:10.1155/2015/972313 ↩
  18. Bakopoulou A, About I. Stem cells of dental origin: current research trends and patents. Recent Patents on Biotechnology. 2016;10(1):55-72. doi:10.2174/1872208310666160728103743 ↩
  19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  20. Hynes K, Menicanin D, Gronthos S, Bartold PM. Clinical utility of stem cells for periodontal regeneration. Periodontology 2000. 2012;59(1):203-227. doi:10.1111/j.1600-0757.2012.00443.x ↩